Adding dinutuximab beta to chemotherapy for advanced Ewing sarcoma
Treatments studied
Part of Cancer clinical trials.
This trial tests whether adding a drug called dinutuximab beta to standard chemotherapy can help treat Ewing sarcoma that has spread. It is for people whose tumors have a specific marker (GD2) and are receiving their first treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 1 year or older.
- Diagnosed with Ewing sarcoma or a similar type of bone or soft tissue cancer.
- Cancer has spread to other parts of the body (metastatic).
- Tumor tests positive for a specific marker called GD2.
- Starting the standard first-line chemotherapy (VDC/IE) or have completed the initial 4 cycles.
- Good overall health: adequate organ function (kidney, liver, heart, bone marrow), and no serious infections or other cancers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized radiation therapy that adjusts the dose based on your tumor. It aims to improve treatment for Ewing sarcoma while limiting side effects.
This trial tests whether adding immunotherapy (a treatment that helps your immune system fight cancer) to chemotherapy can help young people whose bone or soft tissue sarcoma has come back or hasn't responded to previous treatment.
This trial is testing a new drug called xaluritamig for children, teens, and adults with Ewing sarcoma that has come back or is not responding to treatment. The goal is to see if this drug can shrink the cancer or stop it from growing.
This study tests a new way of giving a chemotherapy drug called irinotecan (in a liposome form) along with two other chemotherapy drugs (temozolomide and vincristine) versus the standard form of irinotecan with the same two drugs, for people with advanced Ewing's sarcoma. The goal is to see if the new version is safer and works better.
This trial tests a combination of three drugs (dinutuximab beta, irinotecan, and rapamycin) for people with bone cancers like osteosarcoma or Ewing sarcoma that have come back or not responded to treatment. The goal is to see if this combination can shrink or slow the tumors.
This trial tests a new schedule of standard chemotherapy drugs to see if it improves outcomes for people with metastatic Ewing sarcoma or CIC-rearranged sarcoma. It is for patients who have not had prior cancer treatment, except possibly one initial cycle of VDC.
Hear when a new High-risk GD2-Positive Ewing Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.